US/UK/Canada

Share

Pick a time period -
Tags ( Active)

INTERIM REPORT JANUARY 1st 2023 – MARCH 31st 2023

SELECTIMMUNE PHARMA IN BRIEF   · Antibiotic resistance is a global, rapidly growing health concern. The World Health Organization (WHO) has declared antibiotic resistance a major threat to global health. · SelectImmune Pharma is an innovative biotech company that develops novel therapies against infection. · These therapies are designed to inhibit excessive innate immune responses to infection, which are a major cause symptoms and pathology. · Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including

Introducing Hamlet BioPharma to investors

Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing Hamlet BioPharma, providing a first overview of the company, recent transactions and the main projects. A merger of HAMLET Pharma and SelectImmune Pharma was formally decided on May 17[th], 2023. The decisions were taken by extra general assemblies in the respective companies. The transaction also includes the acquisition of a tuberculosis project and a collaboration agreement with Linnane Pharma. The formal

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden and who wish to accept the proposed merger consideration must carry out closer investigations regarding the applicable legislation and possible tax consequences. The two pharmaceutical companies Hamlet

INTERIM REPORT OCTOBER 1st 2022 – DECEMBER 31st 2022

SELECTIMMUNE PHARMA IN BRIEF SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. • Excessive innate immune responses to infection cause symptoms and pathology in acute pyelone phritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these condi tions as alternatives or complements to antibiotics. • Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. • One drug

SelectImmune Pharma AB publishes video from digital investor meeting

SelectImmune Pharma AB publishes video from digital investor’s meeting SelectImmune Pharma AB has published a video from the digital investor’s meeting held in conjunction with the company's Annual General Meeting in November 2022. The video is now available on the company's website. In this video, chairman Catharina Svanborg and CEO Gabriela Godaly present provided an overview of the company's progress and discuss future goals for the development of infectious disease therapies. Positive results were presented for the treatment of Bladder Pain Syndrome with the drug candidate IL-1RA as

Communiqué from the Annual General Meeting of SelectImmune Pharma AB

On November 23, 2022, SelectImmune Pharma AB (publ) hekd its annual general meeting. A summary of the decisions made are listed below. All decisions were made unanimously.Determining the income statement and balance sheet as well as distribution of income The meeting decided to determine the income statement and balance sheet as included in the presented annual report. The meeting decided to dispose of the company's results according to the board's proposal in the annual report. Furthermore, it was decided that no dividend will be paid for the financial year 2021/2022.

SelectImmune Pharma holds a digital investor meeting

SelectImmune Pharma is inviting you to a digital investors’ meeting via Zoom, on Tuesday November 29th at 12.00 CET, for dialogue and to follow up from the General meeting. We welcome existing owners, other investors and interested parties to join. The meeting participants will be informed of the company developments and will be invited to ask questions. These may be asked online during the meeting or be sent via e-mail to the addresses listed below. Please use this link to participate:   https://us06web.zoom.us/j/84640256743?pwd=dDFtNEVJWTJBaVV4ZGp3K3pZWkFBdz09 Meeting ID: 846

SelectImmune Pharma Interim report Q1 2022/2023

SELECTIMMUNE PHARMA IN BRIEF • SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. • Excessive innate immune responses to infection cause symptoms and pathology in acute pyelonephritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these conditions as alternatives or complements to antibiotics. • Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. • One drug

First patient in – a new treatment option for patients with bladder pain

As previously announced, SelectImmune Pharma has successfully completed preparations to start a controlled clinical trial in patients with bladder pain syndrome (severe pain in the bladder). We can now announce that the study has started and the first patient has been included in the study. The patients must be treated with the drug Kineret, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA).Patients with bladder pain syndrome have severe pain of unknown cause. Many different treatments have been tried without lasting positive effects. The development of new, more precise drugs

Magnus Nylén proposed as new member of the SelectImmune Pharma board

Shareholders, who at the time of this press release in total represent more than 50 percent of all votes, have amended their previous proposal to the upcoming Annual General meeting on November 23[rd] concerning the election of chairman of the meeting, board of directors, auditor, and remuneration to the board of directors and auditor (items 2 and 10-15) to the following proposal. Jan Zetterberg, who is the company's lawyer, is proposed as chairman of the meeting. Furthermore, five board members are proposed without a deputy. Fee for the chairman of the board is not paid, a fixed fee of

YEAR-END REPORT JULY 2021 – JUNE 2022

SELECTIMMUNE PHARMA IN SHORT · SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. · Excessive innate immune responses to infection cause symptoms and pathology in acute pyelonephritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these conditions as alternatives or complements to antibiotics. · Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. · One

A publication in Nature Reviews Urology summarizes the scientific basis for SelectImmune’s drug development strategy.

“Immunomodulation therapy offers new molecular strategies to treat urinary tract bacterial infections” – a publication in Nature Reviews Urology summarizes the scientific basis behind SelectImmune’s drug development strategy. The review also describes successful examples of innate immunomodulation therapy.  Butler, D., Ambite, I., et al. Immunomodulation therapy offers new molecular strategies to treat UTI. Nature Reviews Urology (2022). DOI: 10.1038/s41585- 022-00602-4. Innovative solutions are needed for the treatment of bacterial infections and a range of

SelectImmune Pharma Interim report Q3 2021/2022

SELECTIMMUNE PHARMA IN SHORT · SelectImmune Pharma is an innovative biotech company, developing novel immunotherapies. · Excessive innate immune responses to infection cause symptoms and pathology in acute pyelonephritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these conditions as alternatives or complements to antibiotics. · Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. · One drug candidate,

SelectImmune Pharma appoints acting CEO

The company is delighted to announce that Gabriela Godaly will take the role as acting CEO of SelectImmune Pharma until a new permanent CEO has been appointed.Professor Godaly is familiar with all aspects of the company and has been actively involved in its development for several years. She was appointed Chief Medical Officer of SelectImmune Pharma in 2020 and has served on the Board of Directors since 2019. Gabriela Godaly is a clinical trials expert and her contributions are extremely valuable for the rapidly evolving clinical trials program of SelectImmune Pharma.  For more

SelectImmune Pharma receives approval to conduct a placebo-controlled clinical study of Bladder Pain

Selectimmune Pharma is pleased to announce that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome.Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the

SelectImmune Pharma releases new film about immunotherapy

Today we are proud to present a new film entitled “Immunotherapy - a complement to antibiotics’’. The film tells the story about SelectImmune Pharma’s drug development program and the scientific discoveries that have defined new and exciting tools for treating infections. SelectImmune is developing several drug candidates with exciting potential. In the film you will meet the multinational and talented research team and hear their stories about their favourite molecules and technologies. You will also meet Dr. Björn Wullt, who has used innate immunotherapy to treat patients with bladder

Correction: SelectImmune Pharma AB to conduct clinical trials in cystitis and bladder pain syndrome

As of March 29[th], SelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi®) to buy Kineret® (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome.Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation

Correction: SelectImmune Pharma AB to conduct clinical trials in cystitis and bladder pain syndrome

As of March 29[th], SelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi®) to buy Kineret® (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome.Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation

Correction MAR label – SelectImmune Pharma’s CEO recruited to new position

The correction refers to the MAR label. This press release should be without the MAR label. Selectimmune Pharma’s CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.”We are grateful for the contributions of Ms Gidner and wish her all the best in her next position,” says Catharina Svanborg, Chairman of the board, SelectImmune Pharma. For more information, please contact:

SelectImmune Pharma’s CEO recruited to new position

Selectimmune Pharma’s CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.”We are grateful for the contributions of Ms Gidner and wish her all the best in her next position,” says Catharina Svanborg, Chairman of the board, SelectImmune Pharma. For more information, please contact: Catharina Svanborg Chairman of the board SelectImmune Pharma AB Phone: +46 709 42 65 49 E-

SelectImmune Pharma Interim report Q2 2021/2022

SIGNIFICANT EVENTS On November 2nd, The SelectImmune Pharma Annual Report for the fiscal year of 2020/2021 was published. It may be found on the company homepage. On November 24th, The SelectImmune Pharma Annual General Meeting was held. Considering the covid pandemic situation, the AGM was held through mail voting as per temporary Swedish law. On December 7th, a virtual investors’ meeting was given via link and was well attended. A company presentation was given to follow up from the Annual General Meeting, and an active Q&A session followed. A recording of the meeting is

SelectImmune Pharma’s CMO and Board member Gabriela Godaly promoted to Professor at Lund University

Selectimmune Pharma is pleased to announce the promotion of its Chief Medical Officer (CMO) and Board member Dr. Gabriela Godaly to Professor of Clinical Microbiology at Lund University as of February 2022.Dr. Godaly received her PhD in 2000 and has since developed a successful, well-funded research group, focusing on the area of tuberculosis and the development of new alternatives to antibiotics for treating these infections. The group studies the immune response, effects of vaccines and new treatment approaches. Dr. Godaly’s group has successfully developed a peptide-based therapy,

Successful technology transfer for production of drug candidate NlpD

The protein drug candidate NlpD, which is being developed by SelectImmune Pharma, needs adequate, large-scale production technology for continued development towards clinical trials. To achieve this goal, SelectImmune Pharma collaborates with the leading international manufacturer Lonza. The production technology has now successfully been transferred as a first step towards larger scale production.The NlpD protein was first identified in “nice bacteria”, which release the protein into human cells where it inhibits the basic protein production machinery, reducing inflammation and excessive

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media